SCHEMBL2656832

SCHEMBL2656832

CCN1Cc2nc3c(-c4cnccc4OC)cccc3c(N)c2C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 6/20 0.49
▸ GABRB3 P28472 6/20 0.49
▸ GABRA2 P47869 6/20 0.49
▸ PDE5A O76074 5/20 0.40
▸ UGCG Q16739 1/20 0.36
▸ LCK P06239 1/20 0.35
▸ BTK Q06187 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ PDE6C P51160 1/20 0.34
▸ ADORA2A P29274 2/20 0.34
▸ GABRA1 P14867 1/20 0.33
▸ GABRA5 P31644 1/20 0.33
▸ GABRA3 P34903 1/20 0.33
▸ CCNC P24863 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922653 0.93 GABRG2 (0.49) GABRG2GABRB3GABRA2PDE5AUGCG
SCHEMBL2661373 0.87 GABRG2 (0.43) GABRG2GABRB3GABRA2PDE5AMEN1
SCHEMBL2657758 0.87 LCK (0.48) GABRG2GABRB3GABRA2LCKBTK
SCHEMBL2661396 0.87 PDE5A (0.43) GABRG2GABRB3GABRA2PDE5AUGCG
SCHEMBL2660894 0.87 GABRG2 (0.42) GABRG2GABRB3GABRA2PDE5AMEN1
SCHEMBL2655510 0.86 PDE5A (0.41) GABRG2GABRB3GABRA2PDE5AUGCG
SCHEMBL2661407 0.86 PDE5A (0.41) GABRG2GABRB3GABRA2PDE5AGAA
SCHEMBL2661359 0.86 TNIK (0.42) GABRG2GABRB3GABRA2MEN1GAA
SCHEMBL4922136 0.86 GABRG2 (0.48) GABRG2GABRB3GABRA2PDE5AUGCG
SCHEMBL2662436 0.86 GABRG2 (0.49) GABRG2GABRB3GABRA2PDE5AGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback